← All Cytokinetics INC filings

Cytokinetics INC Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics CEO Sells Shares
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on August 10, 2026 for $76.76 per share.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Executive Sells Shares
Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 14,000 shares of common stock on July 30, 2026 for $79.88 per share.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics CEO Sells Shares
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on July 27, 2026 for $80.87 per share.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Executive Sells Shares
Fady Ibraham Malik, EVP Research & Development of Cytokinetics Inc, sold 3,500 shares of common stock on July 21, 2026 for $80.59 per share.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Director Receives Stock Grant
Nancy Wysenski, a Director of Cytokinetics Inc, received 75 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Director Receives Stock Grant
Wendell Wierenga, a Director of Cytokinetics Inc, received 75 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Director Receives Stock Grant
Edward M. Kaye, a Director of Cytokinetics Inc, received 151 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Director Receives Stock Grant
John T Henderson, a Director of Cytokinetics Inc, received 272 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Director Receives Stock Grant
Robert Arthur Harrington, a Director of Cytokinetics Inc, received 151 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Director Receives Stock Grant
James M Daly, a Director of Cytokinetics Inc, received 151 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics CEO Sells Shares
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on July 13, 2026 for $82.02 per share.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics EVP Buys Stock, Sells Options
Cytokinetics EVP of Research & Development, Fady Ibraham Malik, acquired 3,500 shares of common stock and disposed of 3,500 stock options.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Insider Trades: CEO Sells Shares
Cytokinetics CEO Robert I. Blum reported a sale of 7,500 shares of common stock on July 1, 2026, for $84.92 per share.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics EVP Sells Shares, Buys Options
Cytokinetics EVP Andrew Callos engaged in a series of transactions, selling 15,000 shares of common stock and acquiring 15,000 stock options.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Insider Trades: CFO Acquires Shares
Cytokinetics' CFO, Lee Sung, acquired 1,112 shares of common stock and exercised a stock option for the same amount on July 1, 2026, as reported in a Form 4 filing.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics CFO Trades Shares and Options
Cytokinetics EVP, Chief Financial Officer Lee Sung reported transactions involving the acquisition and disposition of common stock and stock options on June 24, 2026.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Insider Trades: CFO Acquires Shares
Cytokinetics' CFO, Lee Sung, has acquired a significant number of company shares through various stock option exercises and purchases.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Insider Trades: CEO Acquires Shares
Cytokinetics Inc. reports that President & CEO Robert I. Blum acquired 7,500 shares of common stock on June 15, 2026, for $70.46 per share.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics EVP Malik Executes Stock Option Exercise
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised 3,500 stock options and sold the resulting shares.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Director Edward Kaye Sells Cytokinetics Shares
Cytokinetics Director Edward M. Kaye sold 2,933 shares of common stock on June 1, 2026, pursuant to a Rule 10b5-1 trading plan.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Executive Executes Stock Option Exercise
EVP and Chief Commercial Officer Andrew Callos exercised 15,000 stock options and sold the resulting shares.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Director B. Lynne Parshall Sells Cytokinetics Shares
Director B. Lynne Parshall sold 5,000 shares of Cytokinetics Inc. common stock on June 1, 2026, at a price of $74.08 per share.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics CEO Robert Blum Sells 7,500 Shares
Cytokinetics President and CEO Robert I. Blum sold 7,500 shares of common stock at an average price of $77.21.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Director Muna Bhanji Increases Stake in Cytokinetics
Director Muna Bhanji acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Director James Daly Reports Equity Grant
Director James M. Daly acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics, Inc.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Director Harrington Receives Equity Grant
Director Robert Arthur Harrington acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Director John T. Henderson Increases Cytokinetics Stake
Director John T. Henderson acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Director Kaye Receives Equity Grant
Director Edward M. Kaye acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics, Inc.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Director B. Lynne Parshall Equity Grant
Director B. Lynne Parshall acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.
NASDAQ
CYTK
Cytokinetics INC
Form 4: Cytokinetics Director Robert Landry Receives Equity Grant
Director Robert E. Landry acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics, Inc.